Skip to main content

Dr. Ephraim E. Parent, MD

Nuclear Medicine (Nuclear Medicine Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
1,107

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Nuclear Medicine Physician primary
    FL license ME137212
  • Nuclear Radiology Physician
    MO license 2013009624

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Nuclear Medicine per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,107
Services billed
5,029
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Gallium ga-68, dotatate, diagnostic, 0.1 millicurie1,66730
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries483437
Nuclear medicine study from skull base to mid-thigh with ct scan458424
Gallium ga-68 gozetotide, diagnostic, (locametz), 1 millicurie34953
Technetium tc-99m sestamibi, diagnostic, per study dose346179
Nuclear medicine studies of heart muscle at rest and with stress and spect166166
Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging163163
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries157155
Nuclear medicine study whole body with ct scan11597
Nuclear medicine study of bone and/or joint whole body6261

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Payments from drug and device companies

In 2025, 7 companies reported 20 payments worth $34,311 in total to this clinician.

By company
Blue Earth Diagnostics$27,993
E.r. Squibb & Sons, L.l.c.$4,479
Telix Pharmaceuticals$1,440
Progenics Pharmaceuticals, Inc.$139
GE Healthcare$117
Novartis Pharmaceuticals Corporation$115
Siemens Medical Solutions USA, Inc.$28.77
By type
Consulting Fee$19,404
Travel and Lodging$10,960
Honoraria$3,300
Food and Beverage$647

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 4, 2025Blue Earth Diagnostics
Oct 4, 2025
Travel and Lodging
POSLUMA · Diagnostic Imaging · travel to Barcelona, Spain · in-kind
$10,072
Dec 5, 2025Blue Earth Diagnostics
Dec 5, 2025
Consulting Fee
Axumin · Diagnostic Imaging
$7,925
Nov 2, 2025Blue Earth Diagnostics
Nov 2, 2025
Consulting Fee$4,950
Oct 9, 2025E.r. Squibb & Sons, L.l.c.
Oct 9, 2025
Consulting Fee$4,479
Apr 17, 2025Blue Earth Diagnostics
Apr 17, 2025
Honoraria
POSLUMA · Diagnostic Imaging
$3,300
Mar 13, 2025Telix Pharmaceuticals
Mar 13, 2025
Consulting Fee$1,200
Mar 21, 2025Blue Earth Diagnostics
Mar 21, 2025
Consulting Fee
Axumin · Diagnostic Imaging
$850
Oct 4, 2025Blue Earth Diagnostics
Oct 4, 2025
Travel and Lodging
POSLUMA · Diagnostic Imaging · travel to Barcelona, Spain · in-kind
$808
Oct 4, 2025Blue Earth Diagnostics
Oct 4, 2025
Travel and Lodging
POSLUMA · Diagnostic Imaging · travel to Barcelona, Spain · in-kind
$80.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $552,232 in research payments for these studies, mostly to the institutions running them.

  • Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
    E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05595460
  • LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor
    Novartis Pharmaceuticals Corporation
  • Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
    Novartis Pharmaceuticals Corporation
  • A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Nuclear Medicine clinicians in Jacksonville

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 1, 2020), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1174834576. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.